Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,341 result(s) found. Displaying page 1,658 of 2,218.
    «« First « Previous 1654  1655  1656  1657  1658  1659  1660  1661  1662  Next» Last»»
    EudraCT Number: 2023-000604-19 Sponsor Protocol Number: R2810-ONC-1690 Start Date*: 2023-08-30
    Sponsor Name:Regeneron Pharmaceuticals Inc.
    Full Title: A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients with Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN281...
    Medical condition: Relapsed Solid Tumor Refractory Solid Tumor Relapsed Central Nervous System Tumor Refractory Central Nervous System Tumor Diffuse Intrinsic Pontine Glioma High Grade Glioma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007958 Central nervous system neoplasm PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000282-20 Sponsor Protocol Number: EBS-101-OL-001 Start Date*: Information not available in EudraCT
    Sponsor Name:Emalex Biosciences, Inc.
    Full Title: A Multicenter, Open-Label, Extension Study Intended to Evaluate the Long-term Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette’s Syndrome
    Medical condition: Children and Adolescent Subjects with Tourette’s Syndrome greater than or equal to 6 and less than or equal to 18 years of age
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-005101-39 Sponsor Protocol Number: ORION-LVAD-1 Start Date*: 2018-06-06
    Sponsor Name:Hannover Medical School
    Full Title: A phase IV study to explore the safety of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with heart failure carrying Left Ventricular Assist Devices (ORION-LVA...
    Medical condition: Patients with iron deficiency anemia and heart failure carrying left ventricular assist devices (LVAD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001491-35 Sponsor Protocol Number: CB103-C-101 Start Date*: 2017-08-11
    Sponsor Name:Cellestia Biotech AG
    Full Title: A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study with Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adu...
    Medical condition: advanced or metastatic solid tumours and haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003106-28 Sponsor Protocol Number: 73841937NSC2001 Start Date*: 2019-11-26
    Sponsor Name:Janssen Research & Development, LLC [...]
    1. Janssen Research & Development, LLC
    2. Yuhan Corporation
    Full Title: A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients with EGFR Mutation Positive Advanced Non-Small Cell...
    Medical condition: Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002878-27 Sponsor Protocol Number: EECT2020 Start Date*: 2021-03-04
    Sponsor Name:Michael Patrick
    Full Title: Endoscopic electrochemotherapy in esophageal cancer – a phase II clinical trial
    Medical condition: Esophageal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004340-30 Sponsor Protocol Number: M15-538 Start Date*: 2020-06-08
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003829-30 Sponsor Protocol Number: RBN-2397-21-002 Start Date*: 2022-02-03
    Sponsor Name:Ribon Therapeutics, Inc
    Full Title: A Phase 1b/2, multicenter, single arm study of RBN-2397 in combination with pembrolizumab in patients with Squamous Cell Carcinoma of the Lung (SCCL)
    Medical condition: Advanced/metastatic NSCLC of squamous cell histology
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004864 10085300 Squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002857-28 Sponsor Protocol Number: C4671002 Start Date*: 2021-08-23
    Sponsor Name:Pfizer Inc.
    Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTI...
    Medical condition: Coronavirus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) BG (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005077-10 Sponsor Protocol Number: MEIN/21/AmNe-Hyp/001 Start Date*: 2022-04-28
    Sponsor Name:Menarini International Operations Luxembourg SA
    Full Title: Open-label, multicenter, multinational, interventional clinical trial to assess efficacy and safety of the extemporaneous combination of nebivolol and amlodipine in grade 1-2 hypertensive patients ...
    Medical condition: Grade 1-2 hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-021659-17 Sponsor Protocol Number: CMMAd/InFe/2011 Start Date*: 2013-08-14
    Sponsor Name:Fundación Pública Andaluza Progreso y Salud
    Full Title: Phase I / II, multicenter, double blind, randomized, comparison of two groups and two doses, to evaluate the safety and efficacy of autologous ASCs in the treatment of fecal incontinence.
    Medical condition: Patients with incontinence faecal
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10056118 Incontinence faecal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-001727-65 Sponsor Protocol Number: IMCL CP12-0606/TRIO-012 Start Date*: 2009-01-28
    Sponsor Name:ImClone Systems Incorporated
    Full Title: Estudio en fase III, multicéntrico, multinacional, aleatorizado, doble ciego de IMC 1121B más docetaxel frente a placebo más docetaxel en pacientes con cáncer de mama HER2 negativo, irresecable, lo...
    Medical condition: Adenocarcinoma de mama HER2 negativo, metastático o localmente recurrente e irresecable. HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) CZ (Completed) SK (Completed) PL (Completed) GB (Completed) GR (Prematurely Ended) IE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005489-37 Sponsor Protocol Number: CSL654_3003 Start Date*: 2014-07-11
    Sponsor Name:CSL Behring GmbH
    Full Title: A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects with Hemophilia B
    Medical condition: Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060614 Hemophilia B (Factor IX) LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Completed) IT (Completed) CZ (Completed) BG (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002223-42 Sponsor Protocol Number: A4091061 Start Date*: 2015-10-12
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB (PF-04383119) IN SUBJECTS WITH CANCER ...
    Medical condition: Metastatic Bone Pain
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049038 Metastatic bone pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Completed) SK (Completed) HU (Completed) RO (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003988-10 Sponsor Protocol Number: GS-US-380-1490 Start Date*: 2016-02-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infec...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005132-26 Sponsor Protocol Number: CA209-025 Start Date*: 2012-09-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Ther...
    Medical condition: Advanced or metastatic (medically or surgically unresectable) clear-cell Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038414 Renal cell carcinoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) DE (Completed) IT (Completed) AT (Completed) HU (Completed) CZ (Completed) DK (Completed) ES (Completed) NO (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003589-10 Sponsor Protocol Number: D419LC00001 Start Date*: 2015-12-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic S...
    Medical condition: Adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have not received prior systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) GR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) PL (Completed) AT (Completed) RO (Completed) FR (Completed) PT (Completed) BG (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003663-35 Sponsor Protocol Number: PBF-680CT-05 Start Date*: 2018-06-13
    Sponsor Name:Palobiofarma S.L
    Full Title: A phase II, double-blind, randomized, parallel-group, placebocontrolled multi-center study to investigate the effect of the adenosine A1 receptor antagonist PBF-680 on forced expiratory volume in 1...
    Medical condition: patients with mild-to-moderate persistent atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10003638 Atopic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005243-28 Sponsor Protocol Number: 212082PCR3010 Start Date*: 2012-03-14
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (PCR)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) HU (Prematurely Ended) ES (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003300-23 Sponsor Protocol Number: EMR100070-007 Start Date*: 2016-06-13
    Sponsor Name:Merck KGaA
    Full Title: A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metas...
    Medical condition: Advanced (unresectable, locally advanced or metastatic) adenocarcinoma of the stomach, or of the gastro-esophageal junction (GEJ)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071114 Metastatic gastric adenocarcinoma LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017761 Gastric cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) RO (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1654  1655  1656  1657  1658  1659  1660  1661  1662  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 05:13:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA